Mutations of β-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors

F Tissier, C Cavard, L Groussin, K Perlemoine… - Cancer research, 2005 - AACR
F Tissier, C Cavard, L Groussin, K Perlemoine, G Fumey, AM Hagneré, F René-Corail…
Cancer research, 2005AACR
Adrenocortical cancer is a rare cancer with a very poor prognosis. The genetic alterations
identified to date in adrenocortical tumors are limited. Activating mutations of the Wnt
signaling pathway have been observed in more frequent cancers, particularly digestive tract
tumors. We investigated whether Wnt pathway activation is involved in adrenocortical
tumorigenesis. In a series of 39 adrenocortical tumors, immunohistochemistry revealed
abnormal cytoplasmic and/or nuclear accumulation of β-catenin in 10 of 26 adrenocortical …
Abstract
Adrenocortical cancer is a rare cancer with a very poor prognosis. The genetic alterations identified to date in adrenocortical tumors are limited. Activating mutations of the Wnt signaling pathway have been observed in more frequent cancers, particularly digestive tract tumors. We investigated whether Wnt pathway activation is involved in adrenocortical tumorigenesis. In a series of 39 adrenocortical tumors, immunohistochemistry revealed abnormal cytoplasmic and/or nuclear accumulation of β-catenin in 10 of 26 adrenocortical adenomas and in 11 of 13 adrenocortical carcinomas. An activating somatic mutation of the β-catenin gene was shown in 7 of 26 adrenocortical adenomas and in 4 of 13 adrenocortical carcinomas; these mutations were observed only in adrenocortical tumors with abnormal β-catenin accumulation and most were point mutations altering the Ser45 of exon 3 (in the consensus GSK3-β/CK1 phosphorylation site). Functional studies showed that the activating Ser45β-catenin mutation found in the adrenocortical cancer H295R cell line leads to constitutive activation of T-cell factor–dependent transcription. This is the first molecular defect to be reported with the same prevalence in both benign (27%) and malignant (31%) adrenocortical tumors. β-Catenin mutations are also the most frequent genetic defect currently known in adrenocortical adenomas. In adrenocortical adenomas, β-catenin alterations are more frequent in nonfunctioning tumors, suggesting that β-catenin pathway activation might be mostly involved in the development of nonsecreting adrenocortical adenomas and adrenocortical carcinomas. The very frequent and substantial accumulation of β-catenin in adrenocortical carcinomas suggests that other alterations might also be involved. This finding may contribute to new therapeutic approaches targeting the Wnt pathway in malignant adrenocortical tumors, for which limited medical therapy is available.
AACR